Showing 2321-2330 of 3039 results for "".
- RxSight Launches LAL+ and Features Multiple Doctor Presentations at ASCRShttps://modernod.com/news/rxsight-announces-commercial-launch-of-the-lal-and-features-multiple-doctor-presentations-at-ascrs/2482213/RxSight announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL and the Light Adjustable Lens+ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small cont
- GenSight Biologics Confirms Sustained Efficacy and Safety of Lumevoq Injections 4 Years After One-Time Administrationhttps://modernod.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-lumevoq-injections-4-years-after-one-time-administration/2482174/GenSight Biologics reported initial efficacy and safety results at 4 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (GS010; lenadogene nolparvovec). The results show that 4 years after a one-ti
- OcuTerra Fails Phase 2 DR:EAM Trial Evaluating Nesvategrast for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-fails-phase-2-dream-trial-evaluating-nesvategrast-for-diabetic-retinopathy/2482163/OcuTerra Therapeutics announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast (OTT166), a novel, selective RGD integrin inhibitor developed as an eye drop. The clinical trial did not meet its primary or key secondary ef
- GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with Lumevoq Gene Therapy at NANOS 2024https://modernod.com/news/gensight-biologics-announces-initial-results-from-new-meta-analyses-on-visual-outcomes-with-lumevoq-gene-therapy-at-nanos-2024/2482159/GenSight Biologics announced initial results of new meta-analyses in Leber Hereditary Optic Neuropathy (LHON), which showed those treated with Lumevoq (GS010; lenadogene nolparvovec) gene therapy experienced a rate of visual recovery greater than that of idebenone-treated patients and untreated (
- MediPrint Ophthalmics Completes Phase 2b Study of Drug-Eluting Contact Lens for Glaucomahttps://modernod.com/news/mediprint-ophthalmics-completion-phase-2b-study-of-drug-eluting-contact-lens-for-glaucoma/2482158/MediPrint Ophthalmics announced it has completed its SIGHT-2 phase 2b study evaluating its lead candidate (LL-BMT1) versus a control group on bimatoprost 0.01% ophthalmic solution. LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens leveraging com
- CoFi Announces Market-Wide Availability of its Multi-Provider Financing Solution with CareCredithttps://modernod.com/news/cofi-announces-market-wide-availability-of-its-multi-provider-financing-solution-with-carecredit/2482133/CoFi announced that patient payments with the CareCredit credit card can now be processed through CoFi’s multi-party payments platform. This market-wide availability follows a successful beta period involving joint CoFi and CareCredit customers. “We’ve
- Alcon to Unveil Updated MARLO App at SECO 2024https://modernod.com/news/alcon-to-unveil-new-marlo-app-at-seco-2024/2482127/Alcon announced it will showcase the new MARLO App at the SECO International meeting in Atlanta. The app includes new features for patients and is now available to download in the Apple App Store. Launched in 2020, MARLO was developed as an online platform to h
- Eversight Partners with Emmecell Biotech to Advance Ocular Cell Therapieshttps://modernod.com/news/eversight-partners-with-emmecell-biotech-to-advance-ocular-cell-therapies/2482124/Global nonprofit eye bank Eversight has partnered with biotech company Emmecell to advance cell therapies for the treatment of eye disease. Financial terms of the deal were not disclosed. Emmecell’s minimally invasive cell therapy injects healthy corneal
- Johnson & Johnson Launches Tecnis PureSee Presbyopia-Correcting IOL in EMEAhttps://modernod.com/news/johnson-johnson-launches-tecnis-puresee-presbyopia-correcting-iol-in-emea/2482116/Johnson & Johnson MedTech announced that its Tecnis PureSee presbyopia-correcting IOL is now available in Europe, the Middle East, and Africa (EMEA). The Tecnis PureSee IOL features a proprietary, purely refractive design that delivers uninterrupted, high-quality, vision with high best-in-cat
- Toku Obtains CE and UKCA Marks for AI Cardiovascular Risk Assessments Through the Eyehttps://modernod.com/news/toku-obtains-ce-and-ukca-marks-for-ai-cardiovascular-risk-assessments-through-the-eye/2482096/Toku announced that it has obtained CE Mark in Europe and UKCA in the United Kingdom for its patented CLAiR technology, which provides a non-invasive evaluation for the risk of cardiovascular disease (CVD) at the point of care using retinal images captured during a routine eye exam